Jump to content


This stream auto-updates     

  1. Last week
  2. Filipinos have a penchant for singing and dancing, hence the education-entertainment approach was used in communicating key themes on immunization. The Department of Health in the Philippines, with support from the World Health Organization, produced the following music videos for the Back to Bakuna (Back to Vaccines) campaign in 2017: Bakwagon (a word play on Bakuna/Vaccine and wagon), a public service announcement aired on TV and radio Baby Come Bak (Baby Come Back), on convincing parents and caregivers to complete their baby's vaccination Limang Bisita (Five Visits), on the schedule of immunization visits May Bakuna para D'yan (There's a Vacccine for That), on vaccines and diseases they prevent Okay Kay Baby (Okay for Baby), on vaccine safety. This music video is not included in the playlist but is exclusively played at health facilities. The music videos are being played at waiting areas of health centers, to supplement the information needs of parents and caregivers while they wait for their child to be vaccinated.
  3. This is a compliation of field guides developed to support communication planners and programme implementers in their communications around human papillomavirus (HPV) vaccination introduction, planning, roll out, and monitoring. They are the result of a collaboration between the United Nations Children's Fund (UNICEF), GAVI, the World Health Organization (WHO), PATH, Girl Effect, the Centers for Disease Control and Prevention (CDC), Clinton Health Access Initiative (CHAI), Jhpiego, United Nations Population Fund (UNFPA), the Bill and Melinda Gates Foundation, American Cancer Society, and PCI Media. Field Guide - HPV Message Framework Field Guide - Interpersonal Communication for HPV Field Guide - HPV Vaccination Branding Field Guide - Digital Dialogue for HPV Vaccination Field Guide - HPV Risk and Crisis Management and more. Global HPV Communication Website for HPV Vaccination Promotion
  4. Earlier
  5. Laura Brennan was diagnosed with terminal cervical cancer in 2016. Following her diagnosis, she worked tirelessly to help others avoid this devastating disease by telling her story and spreading the facts about HPV and the vaccine that can prevent it. Laura passed away in March 2019 at age 26, but her message lives on.
  6. Description of the pertussis immunization program in pregnancy in Murcia´s Region
  7. MMR immunization campaign Murciasalud undertook in migrant adults and it is still ongoing
  8. Description of the campaign we conducted to promote HPV vaccination in preadolescent women
  9. This resource describes all the aspects of the pertussis immunization program in pregnancy.
  10. The Melbourne Vaccine Education Centre (MVEC) is an online initiative which provides up-to-date immunisation information for healthcare professionals, parents and the public. MVEC content aims to address common queries around vaccines and to promote the benefits of immunisation for both children and adults.
  11. Dengue vaccines have been under development since the 1940s, but due to the limited appreciation of global dengue disease burden and of the potential markets for dengue vaccines, the industry’s interest languished throughout much of the 20th century. In recent years, however, the development of dengue vaccines has accelerated dramatically. Sanofi Pasteur’s Dengvaxia® became the first dengue vaccine to be licensed for use in 2015. Today, several other vaccines are in various stages of advanced development, with clinical trials currently underway. Vaccine development for dengue is particularly challenging because dengue fever is caused by one of four related, but distinct, virus serotypes (DENV 1-4). While recovery from infection by one virus provides lifelong immunity against that virus, it provides only partial and transient immunity against the other three. For vaccine development, this means that an effective vaccine against dengue needs to be tetravalent, providing protection against all four dengue viruses. Dengue vaccines will complement, but not replace, prevention methods, such as vector control, already in place. According to the WHO, drawing on the experiences of other vaccine-preventable vector-borne diseases, effective surveillance, prevention and outbreak response tools (vector control and vaccines) must continue to complement each other in reducing the burden of the disease.
  12. Serie of questions and answers such as : What is RTS,S/AS01? What makes RTS,S different from malaria vaccine candidates currently under development? What is the efficacy of the RTS,S vaccine?
  13. The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results from the same trial, including the efficacy of a booster dose.
  14. This document takes into account new and unpublished data that were communicated by Sanofi Pasteur to WHO in November-December 2017. WHO published the recommendations of the Strategic Advisory Group of Experts on Immunization (SAGE) on the use of Dengvaxia® on 27 May 2016 (1), and subsequently a WHO position paper on dengue vaccine on 29 July 2016 (2). Following the disclosure to WHO of new data on Dengvaxia® by its manufacturer, Sanofi Pasteur, as described in more detail below, WHO has initiated a process engaging independent external experts to review the data in detail. This process is expected to lead to revised recommendations from SAGE in April 2018, and to an updated WHO position paper on dengue vaccine thereafter. The purpose of this document, prepared by the WHO Secretariat, is to supplement the WHO position paper on Dengvaxia® of July 2016 until WHO has issued an updated position paper on dengue vaccine, based on advice by SAGE. WHO Secretariat recommends that the July 2016 position paper be read in conjunction with this document. This document replaces a questions and answers document web-posted by WHO on 30 November 2017.
  15. The reconvened Dengue Working Group is asked to review new data on the long-term follow-up of dengue vaccine recipients. This includes data generated by further laboratory testing and analysis related to the long-term safety and efficacy of CYD-TDV Phase 3 trial participants. In particular, the group is asked to review the differential performance of the CYD-TDV vaccine (also known as Dengvaxia®) in subjects seronegative versus seropositive at the time of vaccination. The group is asked to advise on a revision of WHO’s current vaccine recommendations as published in July 2016. The review at SAGE is tentatively scheduled for April 2018. This will lead to the publication of an amended WHO position paper on the use of a dengue vaccine, which will replace the interim recommendation issued by WHO on 22 Dec 2017 (WHO interim position on the use of Dengvaxia®)
  16. WHO published the recommendations of the Strategic Advisory Group of Experts on Immunization (SAGE) on the use of Dengvaxia® on 27 May 2016, and subsequently a WHO position paper on dengue vaccine on 29 July 2016. Following the disclosure of new data on Dengvaxia® by its manufacturer, Sanofi Pasteur, on 29 November 2017 (as described in more detail below), WHO`s Global Advisory Committee on Vaccine Safety (GACVS) and the WHO Secretariat published interim statements on December 7, 2017, and December 22, 2017, respectively. WHO initiated a process engaging independent external experts to review the data in detail, and reconvened the SAGE working group on dengue vaccines. This process has led to revised recommendations from SAGE on 18 April 2018. An updated WHO position paper on dengue vaccine will be published in September 2018. The purpose of this document is to supplement the WHO ”Question and Answer” document from December 22, 2017
  17. At the November 2011 meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization, SAGE noted with concern the impact of reluctance to accept immunization on the uptake of vaccines reported from both developed and developing countries. These reports led SAGE to request the establishment of a working group on vaccine hesitancy. Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination services. Vaccine hesitancy is complex and context specific varying across time, place and vaccines. It includes factors such as complacency, convenience and confidence. (WHO SAGE Vaccine Hesitancy Working Group report)
  18. This page is aimed at providing a listing of existing vaccinology training courses, of varying durations and training modalities (in-person, online, blended), and an easy search process for interested parties looking for a vaccinology course and identifying alternative courses. The information provided on each course at the respective links is the sole responsibility of the persons in charge of their respective websites/courses. The listing of a vaccinology course on this page does not mean an endorsement of its content or any certification of the quality of the teaching approach. All training courses listed on this website have obtained formal endorsement/accreditation from either a tertiary training institution and/ or a training accreditation institution (e.g. Continued medical education). All courses listed, while varying in nature and prerequisites, tend to be advanced courses covering multiple aspects of vaccinology, if not alluding to all aspects. More courses may be available such as national courses targeting health workers or courses of a more focused nature such as courses on vaccine safety.
  19. Short animations of all the infectious diseases in the Dutch NIP.
  20. Having an injection is not something most of us would choose to do. There has to be a good reason for this. And there is! For the last 3 years an increasing number of people have become ill due to meningococcal bacteria. This is a dangerous and infectious bacteria that is easily spread by coughing, sneezing and kissing. Luckily, you can protect yourself and others by being vaccinated with a simple injection. You are receiving this invitation because between 1 May and 31 December this year you will be aged 14.
  21. Brochure 'Get that jab against meningococcal disease'
  22. In 2017, about 760,000 children aged 0 to 19 years received a total of 2,140,000 vaccinations within the National Immunisation Programme. Participation in the National Immunisation Programme was high among children under 10 years of age, despite the drop by around 2-3% for most vaccinations since 2014. An exception in the high participation is the number of girls who were vaccinated against human papillomavirus (HPV), which has declined by 15% since 2016.
  23. To ensure that children receive maximum protection against these diseases, vaccinations are given in four steps. It is essential that children complete the vaccination cycle as scheduled. If your child has not been vaccinated as scheduled, you need to seek medical advice to ensure that your child receives adequate protection.
  24. In this brochure general information is given to young parents about the Dutch NIP. Together with an invitation for the first vaccination this brochure is sent to parents 6 weeks after birth.
  25. Poster in Irish regarding HPV vaccine
  26. There is evidence that the recommendation of a known health professional leads to increased vaccine uptake. Please help to inform parents about the safety and effectiveness of HPV vaccine.
  1. Load more activity
  • Newsletter

    Want to keep up to date with all our latest news and information?

    Sign Up
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue. - Terms of Use - Privacy Policy - Guidelines